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ABSTRACT: Photodynamic therapy (PDT) involves use of a photosensitizer, whose
activation with light leads to the production of singlet oxygen (SOS), generation of
reactive oxygen species (ROS), and initiation of associated cell toxicity. Because a cell’s
mitochondria constitute sites where oxygen levels are high, ROS can be readily
produced, and apoptosis is commonly initiated. Therefore, an ideal PDT agent might be
a potent photosensitizer that could naturally accumulate in mitochondria. Although a
number of mitochondria-targeting moieties, including triphenylphosphine, guanidinium,
and bisguanidium, have been identified, a quantitative comparison of their efficacies in
targeting mitochondria has not been performed. In this study, we have prepared
triphenylphosphine, guanidinium, and bisguanidium derivatives of the FDA-approved
PDT agent verteporfin (Visudyne, benzoporphyrin derivative-monoacid ring A: BPD-
MA) and compared their abilities to induce the intracellular perturbations common to
potent PDT agents. Cellular parameters examined included subcellular localization of
the verteporfin, real-time monitoring of SOS production, quantitation of reactive oxygen
species (ROS) generation, analysis of mitochondria and chromatin integrity, characterization of cytoskeletal disruption and
evaluation of cytochrome C release as a measure of apoptosis. An analysis of these parameters demonstrates that the
triphenylphosphine derivative (0323) has better mitochondria-targeting efficacy, SOS production, and mitochondria membrane
toxicity than either unmodified verteporfin or its guanidinium derivatives. Consistent with this potency, 0323 also induced the
most prominent mitochondria swelling, actin depolymerization, pyknosis, and cytochrome C release. We conclude that
triphenylphosphine has a better mitochondria-targeting moiety than guanidinium or bis-guanidinium and those PDT
photosensitizers with improved cytotoxicities can be prepared by conjugating a mitochondria-targeting moiety to the desired
photosensitizer.
■ INTRODUCTION
Photodynamic therapy (PDT) combines light energy, oxygen,
and a light-absorbing molecule called a photosensitizer to
induce an oxidative stress in the illuminated (usually neo-
plastic) cells.1 Each of these components is nontoxic by itself,
but, when combined, can induce a chain of reactions leading to
the production of reactive oxygen species (ROS) causing cell
death. The photosensitizer (PS) is a molecule that can absorb a
photon that excites an outer shell electron to a singlet state
(S1), which can then either return to its ground state (i.e., by
fluorescence or heat emission) or undergo intersystem crossing
to a triplet state,2 which can then react with oxygen to generate
free radicals (type I reaction) or singlet oxygen species (type II
reaction). These reactive oxygen species then undergo a series
of downstream reactions to cause oxidative damage.3
One of the challenges in photodynamic therapy (PDT) is to
develop novel photosensitizers that can improve the therapeutic
efficacy without imposing undesirable requirements for
prolonged/enhanced exposure to activating light. The major
parameter used to compare the potencies of different
photosensitizers is singlet oxygen quantum yield (ϕΔ), which
is the efficiency by which a photosensitizer uses light energy to
convert molecular oxygen to singlet oxygen.4 Photosensitizers
that contain the highest ϕΔ are desirable because singlet oxygen
is a powerful oxidant that can directly induce cellular toxicity.
However, it has been demonstrated that a direct correlation
between singlet oxygen production and cell death does not
exist, but rather the toxicity of PDT depends on the subcellular
localization of the PDT agent.5 Because singlet oxygen is highly
reactive and readily quenched (its lifetime is of the order of 40
ns and its diffusion radius is ∼20 nm6), its site of production
will almost certainly be its site of oxidative damage (i.e., a
mammalian cell’s diameter is of the order of ∼10−30 μm and
mitochondria organelles are ∼900 nm wide).7 The solution, if
achievable, would be to target a PDT agent specifically to an
organelle where SOS/ROS could be efficiently produced and
the toxic effects of SOS/ROS would be sensitively experienced.
Based on the reports that mitochondria contain high
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concentrations of oxygen9 and that even low levels of singlet
oxygen produced in the mitochondria are more toxic than large
amounts produced in the nucleus,8 it seemed logical to try to
develop a photosensitizer that would target the mitochondria.
Additional observations that the mitochondria are decisive
regulators of apoptosis and that these organelles produce most
of the cell’s energy only added motivation to this objective.10,11
Indeed, most of the clinically approved photosensitizers
including Foscan,12 Photofrin,13 and Visudyne14 already
partially localize to the mitochondria.
Methods to improve mitochondria targeting have included
conjugation of such mitochondria-targeting moieties as
guanidinium, bisguanidinium, or triphenylphosphine groups
to the main compound to introduce a delocalized positive
charge and increase the compound’s lipophilicity, which
collectively are thought to increase a conjugate’s affinity for
mitochondria. A previous study by Sibrian-Vazquez et al.
showed an increased localization of porphyrin compounds to
the mitochondria upon synthesizing their guanidinium and
bisguanidinium derivatives.15 Although these guanidinium and
bisguanidinium were shown to localize to the mitochondria, the
modified compounds were never compared to the parent
compound, making it unclear whether these molecules actually
increased mitochondria localization. Triphenylphosphine group
is another extensively studied mitochondria-targeting moiety
that has been used for the delivery of chemotherapeutics,16−19
antioxidants,20 imaging probes,21 photosensitizers,22−24 and
other molecules.25 However, to our knowledge, there has not
been a comparison of these moieties in their mitochondria-
targeting efficiencies.
Herein, we present a multimodal comparison of the PDT
agent, verteporfin, with three of its mitochondria-targeted
derivatives in a human head and neck cancer cell line. The
compound verteporfin was chosen because it was already
known to partially concentrate in mitochondria, which if
increased upon conjugation to guanidinium, bisguanidinium, or
triphenylphosphine would provide a robust test of the value of
mitochondrial targeting for maximization of PDT potency.
Moreover, verteporfin is an FDA-approved drug for the
treatment of wet age-related macular degeneration26,27 and
has a longer absorption wavelength than the other mitochon-
dria-targeting photosensitizers mentioned above, which is
desirable to target deeper tissue.
■ RESULTS AND DISCUSSION
The molecules synthesized for this study included 0317, which
contains monoguanidinium group in the carboxyl terminus;
0320, which contains a cyclic bis-guanidinium group that
bridges the carboxyl termini; and 0323, which contains a
triphenylphosphine group on the carboxyl terminus (Figure 1).
As shown in Figure 1, the monoacid ring A of verteporfin was
c o u p l e d t o g u a n i d i n e a n d ( 2 - am i n o e t h y l ) -
triphenylphosphonium bromide 2-(1H-7-azabenzotriazol-1-
yl)-1,1,3,3-tetramethyl uronium hexafluorophosphate methana-
minium (HATU) as a coupling agent to obtain the
monoguanidinium and triphenylphosphonium derivative of
Figure 1. Synthesis of the modified verteporfin to target mitochondria. Reagents and conditions: (i) HATU, diisopropylethylamine (DIPEA),
dimethyl sulfoxide (DMSO), room temperature (r.t.) 30 min then guanidine (2 equiv) stir overnight, (ii) HATU, DIPEA, DMSO, r.t. 25 min then
(2-aminoethyl)triphenylphosphonium bromide (2 equiv) stir overnight, (iii) Me3SnOH (10 equiv), 1,2-DCE, 80 °C, 1 h, (iv) HATU, DIPEA,
DMSO, r.t. 30 min then guanidine (6 equiv) stir overnight.
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verteporfin named 0317 and 0323, respectively. To achieve bis-
and tris-guanidinium derivative of verteporfin for increased
mitochondria-targeting, we tried the conventional methyl ester
hydrolysis conditions to obtain di- and tri- free carboxylic acid
derivative of verteporfin. However, our attempt with strong and
mild basic conditions for methyl ester hydrolysis were
unsuccessful, and we observed complex products in liquid
chromatography−mass spectrometry (LCMS). Finally, we
optimized using Me3SnOH, which had been established by
Nicolaou and co-workers28 to hydrolyze selectively the aliphatic
methyl esters without damaging the olephenic methyl ester in
the E ring of verteporfin. To obtain a tris-guanidinium
derivative of verteporfin, the tri-carboxylic acid derivative was
further conjugated with guanidine using HATU coupling
condition. The reaction was monitored by LCMS, and the
major product shows the molecular weight of 755.2, which is
not that of our expected tris-guanidinium derivative 0319
(MW: 816.9). The LCMS analysis indicates that the isolated
product with the molecular weight of 755.2 was the cyclic bis-
guanidinium derivative 0320.
To compare these compounds, we quantified and compared
their mitochondria localization, intracellular singlet oxygen
production, and mitochondria membrane potential (Δψm)
change. Furthermore, we studied the morphological changes of
the cytoskeleton and mitochondria and reactive oxygen species
production. Because the goal of PDT is to kill pathological cells,
cell death was analyzed by observing nuclear pyknosis and
cytochrome C release from the mitochondria. Results from this
study should facilitate the discovery and optimization of novel
PDT therapeutics by determining which substituent will
promote the most photosensitizer accumulation in the
mitochondria. Moreover, the methods employed here should
help guide development of newer photosensitizers by establish-
ing methods to compare their efficacy.
Cellular Localization of Modified Compounds. The
subcellular fate of the modified compounds was determined by
fluorescent microscopy. Pearson’s correlation coefficient was
used to determine the localization of the photosensitizers
(Figure 2i−l) in the mitochondria, which was labeled with
Mitotracker green (Figure 2e−h). As shown in Figure 2, when
the Mitotracker and 0323 fluorescence images were merged, a
very strong colocalization signal was observed (Figure 2p). The
calculated Pearson’s correlation coefficients (±SEM) were
0.722 (± 0.044) for BPD-MA, 0.678 (± 0.029) for 0317, 0.631
(± 0.029) for 0320, and 0.860 (± 0.012) for 0323. Using a
one-way ANOVA with Tukey post-hoc test, the modified
compound 0323 showed a significantly higher localization to
the mitochondria than BPD-MA (p-value = 0.033), whereas the
other modified compounds showed no difference compared to
BPD-MA.
Figure 2. Localization of BPD-MA and modified compounds in the mitochondria. (a−d) Bright field images of human KB cells. Cells stained with
Mitotracker green (e−h) and photosensitizers (i−l). (m−p) Merged image of green and red channels showing colocalization (yellow) of
photosensitizers and Mitotracker green. (q) Modified compound 0323 showed a significantly higher colocalization compared to BPD-MA using
Pearson’s correlation coefficient and one-way ANOVA with Tukey’s post-hoc test (p = 0.0326). n = 5 images for each group. *p < 0.05. It should be
noted that the photosensitizer fluorescence images do not correlate with the amount of compound intracellularly. These images were modified after
capture to help the readers optimally visualize the intracellular localization of each compound. These adjustments have no effect on the calculation of
colocalization because Pearson’s Correlation Coefficient is independent of pixel intensity/brightness.
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The results demonstrate that verteporfin (BPD-MA) local-
izes to the mitochondria, which agrees with earlier studies
reporting its localization to the mitochondria of pancreatic
cancer cells,32 endothelial cells, and prostate cancer cells.33
There was improved mitochondria targeting of BPD-MA by
using the triphenylphosphine (TPP) moiety, which also agrees
with the literature showing TPP as an effective mitochondria-
targeting molecule.24 Although guanidinium and biguanidinium
have also been used to target the mitochondria, our results
demonstrate that they reduced mitochondria localization of
BPD-MA. The study by Sibrian-Vasquez et al., which showed
an increased mitochondria localization, did not quantify the
localization and compare the synthesized compounds to the
unmodified porphyrins.15 Because porphyrins naturally localize
to the mitochondria, without comparison to an untargeted
control porphyrin, it is difficult to draw any conclusion
regarding the ability of an added substituent to improve
mitochondria localization. Moreover, because BPD-MA, which
is a porphyrin derivative, has already been shown to
significantly localize in the mitochondria, further improvements
may be difficult.
Singlet Oxygen Species Production. The effect of BPD-
MA and its derivatives on intracellular singlet oxygen species
generation was investigated. Previous studies have used singlet
oxygen quantum yield to compare different photosensitizers.
However, these values do not accurately predict the intra-
cellular singlet oxygen production, which depends on the
localization of the photosensitizer and its proximity to oxygen.
Therefore, singlet oxygen sensor green (SOSG), which reacts
with singlet oxygen to produce a highly fluorescent
endoperoxide molecule, was used as a marker of intracellular
singlet oxygen production.34 Due to its low cellular penetrance
as a consequence of extracellular protein binding, the method
described by Choudhury et al. was used.35 Higher intensity of
SOSG fluorescence, which corresponds to an increase in the
singlet oxygen species production, was observed in photo-
sensitizer-treated cells (Figure 3f−i) compared to the non-
treated control group (Figure 4a) following irradiation. To
further determine the singlet oxygen production, fluorescence
intensity was quantified36 using ImageJ’s mean gray value (n =
75 cells) (Figure 4j). There was significantly higher singlet
oxygen production with 0317 (24 142 au ± 451.5) treatment
compared to BPD-MA (21 072 au ± 423.1) treatment after
light irradiation (p-value = 0.001) and with 0323 (35339 au ±
666) treated cells compared to verteporfin (p-value < 0.0001)
and 0317 (p-value < 0.0001) treatment. Treatment with 0320
(18 674 au ± 405.5) did not show any difference from
nontreated cells (17 456 au ± 442.4) (p-value = 0.3944).
We observe the highest production of singlet oxygen species
after irradiation of 0323-treated cells. From the previous
colocalization experiments, it was shown that 0323 had the
greatest accumulation in the mitochondria compared to the
other photosensitizers. Because the mitochondria is an
organelle with the highest intracellular oxygen concentration,9
and because oxygen is required for PDT,37 it was not surprising
that the photosensitizer with the highest mitochondria
localization also had the highest ROS production. It should
also be noted that the excited state energy following near-
infrared (NIR) illumination can be dissipated by multiple
mechanisms, and that compounds that fluoresce efficiently are
usually poor PDT agents and vice versa. Thus, compounds that
efficiently convert excited state energy into emitted fluores-
cence must necessarily have less excited state energy available
for the production of reactive oxygen species (i.e., via
intersystem crossing, formation of singlet oxygen, and further
reaction to generate other ROS). The fact that 0323 has the
lowest fluorescence and highest ROS, whereas BPD-MA has
the highest fluorescence and the lowest ROS is consistent with
this explanation.
Changes in Mitochondria Membrane Potential. Singlet
oxygen is highly reactive and damaging to membranes.38 Thus,
we hypothesized that the increased production of singlet
oxygen in mitochondria will cause damage to its membranes.
To test this hypothesis, we measured the mitochondria
membrane potential (Δψm) with the JC-1 assay. JC-1 is a
cationic dye that accumulates in the mitochondria depending
on the Δψm.
39 During low Δψm, low concentrations of JC-1
localize in the mitochondria, forming mostly monomers that
emit green fluorescence. However, with higher Δψm, there is an
increased concentration of JC-1 in the mitochondria, leading to
Figure 3. Intracellular singlet oxygen production after irradiation. (a) KB cells with no drug. (b−e) Fluorescence of photosensitizers and (f−i)
corresponding intracellular singlet oxygen production. (j) Singlet oxygen quantification after light treatment shows statistically significant increase in
BPD-MA-treated (p-value < 0.0001), 0317-treated (p-value < 0.0001), and 0323-treated (p-value < 0.0001) cells compared with no drug; 0317-
treated (p-value = 0.001) and 0323-treated (p-value < 0.0001) compared to BPD-MA-treated cells; and 0323-treated (p-value < 0.0001) compared
with 0317-treated cells. Statistics were done using one-way ANOVA with Tukey post-hoc analysis. n = 75 cells for all groups. # used for comparison
with no drug, * for comparison with BPD-MA and $ for comparison with 0317. ***p < 0.001, ****p < 0.0001. It should be noted, contrary to the
previous figure, the postcapture parameters (i.e., LUTs) for the photosensitizer fluorescence images were constant in this figure to provide the viewer
with a visual measure of the relative fluorescence of each molecule.
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the formation of JC-1 aggregates that emit red fluorescence.
Quantitative analysis of Δψm was performed by ratiometric
analysis40 of green monomer (green channel) to red aggregate
(red channel) (Figure 4k). The ratio of monomer to aggregate
fluorescence was used as a surrogate for analyzing the Δψm
change. Before light irradiation, no difference between control
and photosensitizer groups was observed, indicating no dark
toxicity. As expected, the ratio of green monomer to red
complex gradually increased during longitudinal observation for
12 min in BPD-MA-treated cells, indicating the decline of
Δψm.41 The modified compound 0323, which previously
showed the highest localization in the mitochondria and
greatest singlet oxygen production, also exhibited the largest
Δψm toxicity, which was significantly higher from 6 min onward
(p = 0.002 at 6 min, p < 0.0001 at 8 min, p < 0.0001 at 10 min,
and p < 0.0001 at 12 min) compared to BPD-MA (Figure 4k).
As expected, the mitochondria membrane potential was
decreased after 690 nm irradiation in photosensitizer-treated
KB cells and the magnitude of depolarization directly correlated
with the extent of mitochondria localization. Thus, the
compounds BPD-MA and 0323 had the greatest mitochondrial
localization and the highest Δψm toxicity. As noted above,
singlet oxygen species are short lived and have a diffusion radius
of only 20 nm, requiring that the location in which they are
produced also be the site where they cause the most damage.
Consistent with this, the superior accumulation of BPD-MA
and 0323 in the mitochondria agrees with the greater observed
damage to Δψm. Furthermore, our longitudinal study revealed a
decline in membrane potential before mitochondria swelling,
Figure 4. Changes in mitochondria membrane potential. JC-1 signal in control cells (a, b) and cells treated with BPD-MA (c, d), 0317 (e, f), 0320
(g, h), and 0323 (i, j) directly after (a−i) and 12 min (b−j) after irradiation. (k) Green-to-red channel ratio during longitudinal study for 12 min
upon irradiation. Higher ratio corresponds to reduction in membrane potential. 0323-treated cells show significant reduction in mitochondria
membrane potential at 6 min (p = 0.002), 8 min (p < 0.0001), 10 min (p < 0.0001), and 12 min (p < 0.0001). Statistical analysis was done using 2-
way ANOVA (n = 20 cells for time = −1 for all groups; n = 30 for nontreated group thereafter and n = 40 for photosensitizer groups). **p < 0.01,
****p < 0.0001.
Figure 5. Qualitative changes observed in cytoskeleton, mitochondria morphology, and ROS following irradiation. (a−d) Actin cytoskeleton in
nontreated cells and photosensitizer-treated cells. (e−h) Mitochondria morphology studies. (i−l) Changes in ROS production following light
irradiation. (l) Apoptotic body indicated by the arrow.
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suggesting this phenomenon may be an event preceding early
processes associated with apoptosis. Because the compound
0320 did not show a significant increase in SOS or change in
Δψm in KB cells, this compound was not further studied.
Qualitative Changes: Actin, Mitochondria, and ROS
Production. The next step in evaluating BPD-MA and its
modified derivatives was to study the morphological changes in
the cytoskeleton and mitochondria together with the
production of reactive oxygen species (ROS) following
irradiation. Nontreated cells displayed fibrous structures of
actin filaments (Figure 5a), whereas BPD-MA-treated (Figure
5b), 0317-treated (Figure 5c) and 0323-treated (Figure 5d)
cells showed fragmentation of the actin filaments. Importantly,
0317-treated cells showed less fragmentation and more
polymerized actin than BPD-MA- and 0323-treated cells.
Granular swelling of the mitochondria, which is a sign of cell
damage, was also more prominent in BPD-MA-treated (Figure
5f) and 0323-treated (Figure 5h) cells compared to control
(Figure 5e) and 0317-treated (Figure 5g) cells, which showed a
normal tubular mitochondria structure. There was also an
increase in ROS in BPD-MA-treated (Figure 5j), 0317-treated
(Figure 5k), and 0323-treated (Figure 5l) cells compared to
control cells (Figure 5i). Curiously, the greatest increase in
reactive oxygen species was found to be in the nucleus,
suggesting a significant effect of PDT on the reactive oxygen
species production in the nucleus42 and/or mitochondria
nucleus retrograde signaling.43 This prediction is supported by
our finding of early signs of cell injury and pyknosis (next
section)44 upon initiation of PDT. Interestingly, 0323-treated
cells showed apoptotic bodies indicated by the arrow in Figure
5l, which will be investigated further in a section below.
We believe that the above chain of events begins with 0323
and BPD-MA localization in the mitochondria and their
subsequent generation of reactive species, which then lead to
mitochondrial membrane depolarization and loss of its
integrity. Considering the integral role the mitochondrial
membrane plays in the regulation of electrolyte balance,45 its
deterioration can be expected to bring about a charge
imbalance that will cause mitochondria swelling. The
mitochondria membrane potential is crucial for ATP
production through oxidative phosphorylation.45 Actin assem-
bly and disassembly, which are essential for the structural
integrity of the cell,46 molecular signaling within the cell,47 and
mitochondria motility,48,49 are dependent on ATP for their
regulation. Therefore, damaging the Δψm will lead to its
depolymerization, as shown in this study.
Analysis of Cell Death. Viability assays were then
performed using propidium iodide on photosensitizer-treated
KB cells irradiated with 690 nm light. Four different treatment
groups were examined, namely a control group, which
consisted of KB cells treated with no photosensitizer (Figure
6a) and treated groups preincubated with BPD-MA (Figure
6b), 0317 (Figure 6c) or 0323 (Figure 6d). As shown in Figure
6, after irradiation, propidium iodide staining was only observed
in photosensitizer-treated cells, with 0323 showing the greatest
cytotoxicity (93% PI positive), 0317 demonstrating an
intermediate toxicity (54% positive), and BPD-MA displaying
the lowest cytotoxicity (25% positive). Pyknosis, which involves
an irreversible condensation of chromatin, was also observed.
Apoptosis Through Cytochrome C Release from the
Mitochondria. Considering the roles of mitochondria
damage50 and actin network disassembly51 in mediating
apoptosis, we evaluated the most effective photosensitizer to
this point (0323) and the parent compound (BPD-MA) for the
release of cytochrome C as a measure of one of the hallmarks of
apoptosis. Two major mechanisms of cell death consist of
necrosis and apoptosis. Apoptosis is desirable in PDT because
it minimizes inflammation to adjacent normal tissue.52 One of
the first events that occurs in apoptosis is the release of
cytochrome C from the inner membrane of the mitochondria
to the cytosol.53 Whereas release of cytochrome C from
mitochondria was prominent in BPD-MA-treated (Figure 7b)
and 0323-treated (Figure 7c) cells, little if any cytochrome C
release was observed from the mitochondria in control cells
(Figure 7a). This is consistent with previous studies, which
have shown that BPD-MA induces apoptosis.54,55 Moreover,
apoptotic bodies, which are hallmarks of cell apoptosis,56 can be
observed in the photosensitizer-treated groups (see arrows).
Another function of cytochrome C upon release from the
mitochondria is to induce chromatin condensation following its
translocation to the nucleus.57 Interestingly, cytochrome C is
localized more in the nucleus of 0323-treated cells than in
BPD-MA-treated cells. This study shows PDT with the
Figure 6. Modified compounds reduce cell viability following irradiation. KB cells were incubated for 1 h with either no photosensitizer or 50 nM
BPD-MA, 0317, or 0323 and exposed for 5 s to the NIR laser light. After 1 h, the cells were incubated with Hoechst dye (nuclear stain) and
propidium iodide (vitality stain) before evaluation by fluorescence microscopy. (a−d) Merged images of Hoechst (blue) and propidium iodide
(magenta) are shown, where dead cells appear magenta.
Figure 7. Induction of apoptosis following PDT. (a) Cytochrome C
localization in KB cells with no photosensitizer. Cytochrome C release
in BPD-MA-treated (b) and 0323-treated (c) cells. Arrows indicate
apoptotic bodies.
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modified compound 0323 induces apoptosis similar to BPD-
MA.
■ CONCLUSIONS
In conclusion, we have developed a mitochondria-targeted
photosensitizer by adding a triphenylphosphine (TPP+) group
to carboxyl terminus of the parent PDT agent, verteporfin
(0323). This mitochondria-targeting moiety was more effica-
cious than monoguanidium (0317) or bis-guanidinium (0320)
in targeting the mitochondria. Improving the mitochondria
localization of verteporfin resulted in increased singlet oxygen
species (SOS), depolarization of mitochondria membrane
potential, and cell death. Moreover, elevated actin depolyme-
rization, increased reactive oxygen species, enhanced mitochon-
dria swelling, pyknosis, and apoptosis were also observed. Based
on these observations, we recommend tethering a TPP moiety
to the desired PDT agent when developing a photosensitizer
for cytotoxic applications.
■ EXPERIMENTAL SECTION
Chemicals and Materials. 2-(1H-7-Azabenzotriazol-1-yl)-
1,1,3,3-tetramethyl uronium hexafluorophosphate methanami-
nium (HATU) was obtained from Genscript Inc. (Piscataway,
New Jersey). Guanidine hydrochloride, 1,2-dichloro ethane
(1,2-DCE), diisopropylethylamine (DIPEA), dimethyl sulf-
oxide (DMSO), and all other reagents were purchased from
Sigma-Aldrich. Trimethyltin hydroxide (Me3SnOH) was
purchased from Alfa Aesar. For the synthesis of 0323, (2-
aminoethyl)triphenylphosphonium bromide was synthesized
according to reported procedures.29,30
Synthesis of Mono/Bicationic Derivatives of Verte-
porfin. For synthesis of mitochondria targeted monocationic
derivatives of verteporfin (1 equiv) dissolved in anhydrous
DMSO containing diisopropylethylamine (5 equiv) and HATU
(1 equiv) were stirred for 30 min under argon atmosphere. To
obtain 0317 and 0323, 3-fold molar excess of guanidine
hydrochloride salt and 3-fold molar excess of (2-aminoethyl)-
triphenylphosphonium bromide, respectively, were then added
and stirred overnight at room temperature, as outlined in
Figure 1. The crude products were purified by preparative
reverse phase high-performance liquid chromatography
(HPLC) using a mobile phase of A = 20 mM ammonium
acetate buffer, pH 7; B = acetonitrile; gradient 0−50% B in 30
min, 13 mL min−1, λ = 280 nm. Pure fractions were analyzed by
LCMS and (see Figure S2 in the Supporting Information)
pooled and lyophilized to furnish 0317 and 0323.
For synthesis of the polycationic derivatives of verteporfin,
we used Me3SnOH reagent for mild methyl ester hydrolysis of
verteporfin. Verteporfin (1 equiv) dissolved in anhydrous 1,2-
DCE containing Me3SnOH (10 equiv) was stirred for 1 h at 80
°C. The reaction was monitored by LCMS and the crude
product was purified by preparative reverse-phase HPLC using
a mobile phase of A = 20 mM ammonium acetate buffer, pH 7;
B = acetonitrile; gradient 0−50% B in 30 min, 13 mL min−1, λ
= 280 nm. The methyl ester hydrolyzed verteporfin (1 equiv)
dissolved in anhydrous DMSO containing diisopropylethyl-
amine (5 equiv) and HATU (1 equiv) was stirred for 30 min
under argon atmosphere. A 10-fold molar excess of guanidine
hydrochloride salt was then added and stirred overnight at
room temperature, as outlined in Figure 1. The crude product
was purified by preparative reverse-phase HPLC using a mobile
phase of A = 20 mM ammonium acetate buffer, pH 7; B =
acetonitrile; gradient 0−50% B in 30 min, 13 mL min−1, λ =
280 nm. Pure fractions were analyzed by LCMS and (see
Figure S3 in the Supporting Information) pooled and
lyophilized to furnish 0320. The measured extinction
coefficients of the aforementioned PDT agents were found to
be 3.5 × 104 M−1 cm−1 (BPD-MA), 2.4 × 104 M−1 cm−1
(0317), and 2.2 × 104 M−1 cm−1 (0323).
Cell Culture, Plating. KB cells were cultured with 5 mL of
folic acid (−) RPMI media (Gibco) with 5% fetal bovine serum
(FBS) (Atlanta biologicals) and 1% penicillin/streptomycin
(GIbco) in 25 mL cell culture flasks (Corning, Sigma-Aldrich).
Splitting was done 2−3 times per week or when cell culture
flasks reached about 90% confluence. Cells were plated on 4-
well chambers (Nunc Lab-Tek Chamber Slide System) in 500
μL media and allowed to grow for 2−3 days or when plates
reached 90% confluence. Due to the nature of photosensitizers,
all drug and dye incubations were done in the dark.
Colocalization Experiment. Following cell plating, the
cells were co-incubated with 50 nM drug and 15 nM
Mitotracker green (obtained from Life Technologies) for 1 h
in RPMI media. The cells were then washed two times with
phosphate-buffered saline (PBS) and kept in CO2-independent
media (Life technologies) for imaging. Because the excitation of
the drug may cause morphological changes in the mitochondria
within seconds, Mitotracker green was captured first at 488/
520 nm and photosensitizers were captured at 690 nm.
Singlet Oxygen Experiment. The cells were co-incubated
with 50 nM drug and 10 μM singlet oxygen sensor green
(SOSG, Life Technologies) for 1 h in FBS (−) MEM. They
were washed two times with PBS and kept in CO2-independent
media for imaging. The cells were then irradiated with 690 nm
light followed by SOSG capture at 488/520 nm.
Mitochondria Membrane Potential Experiment. The
cells were incubated with 50 nM BPD-MA, 0317, 0320, or
0323 in RPMI for 1 h followed by two washes with PBS. They
were then incubated in 7.665 μM JC-1 (a probe of
mitochondrial membrane potential; Life Technologies) in
RPMI for 10 min followed by two washes with PBS and kept
in CO2-independent media. JC-1 was captured before
irradiation at 590 nm (J-aggregates) and 529 nm (green
monomers). The cells were then irradiated with 690 nm light.
JC-1 was immediately captured at 590 and 529 nm at 2 min
intervals for 12 min.
Cytoskeleton and Mitochondria Structure Experi-
ment. The cells were incubated with 50 nM BPD-MA,
0317, or 0323 in RPMI for 1 h followed by two washes with
PBS and kept in CO2-independent media. They were then
irradiated using 690 nm light. Cells were then fixed with 4%
PFA for 15 min, permeabilized with 1% Triton X-100 for 30
min and blocked with goat kit31 for 60 min. The cells were then
stained with F-actin green labeling kit (Life Technologies) for
30 min, 1 μM Mitotracker deep-red FM (Life Technologies)
for 30 min, and 1 μg mL−1 Hoechst for 30 min. They were then
washed two times with PBS and images were captured at 520
nm for actin, 461 nm for Hoechst, and 665 nm for
mitochondria stain.
ROS Experiment. The cells were incubated with 50 nM
BPD-MA, 0317, or 0323 in RPMI for 1 h followed by two
washes with PBS. They were then incubated with 5 μM ROS in
RPMI for 30 min followed by two washes with PBS and kept in
CO2-independent media. The cells were irradiated with 690 nm
light and ROS were captured at 488/520 nm.
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Cell Death Experiment. The KB cells were incubated with
50 nM of BPD-MA, 0317, or 0323 diluted in RPMI media for
1 h. They were washed two times with PBS (Gibco), followed
by irradiation for 5 s by the NIR laser light. After 1 h, the cells
were incubated with 5 μg mL−1Hoechst dye (nuclear stain) and
1 μg mL−1propidium iodide (vitality stain) for 30 min. The
cells were then washed two times with PBS, kept in CO2-
independent media, and then imaged at 350/461 and 535/617
nm for Hoechst and propidium iodide dyes, respectively.
Apoptosis Experiment. The cells were incubated with 50
nM BPD-MA or 0323 in RPMI for 1 h followed by two washes
with PBS and kept in CO2-independent media. They were then
irradiated using 690 nm light and then incubated at 37 °C and
5% CO2 for 2 days. The cells were then fixed using 4% PFA for
15 min, permeablized using 1% Triton X-100 for 30 min, and
blocked with a goat kit to prevent nonspecific binding for 30
min. They were then stained with 5 μg mL−1 mouse IgG anti-
cytochrome C (BioLegend) for 20 h and washed three times
with PBS. The cells were then counterstained with Alexa Fluor
594 Goat antimouse antibody (594) for 90 min and washed
three times with PBS. Cytochrome C was then captured using
617 nm emission wavelength.
Microscopy and Imaging Analysis. Images were taken
using Nikon Ti-S epifluorescence microscope equipped with
incubating chamber set at 37 °C and an oil immersion 60×
objective, and the images were obtained with NIS-Elements
software. Colocalization analysis was done using the JACoP
plugin tool in Fiji ImageJ to calculate the Pearson’s correlation
coefficient. Singlet oxygen production analysis was done using
ImageJ to obtain SOSG intensities. Fluorescence intensity map
was obtained using ImageJ. Mitochondria membrane potential
analysis was also done using ImageJ to calculate green-to-red
channel intensity ratio. For ImageJ analysis, the region of
interest feature was selected to precisely quantify the mean gray
value intensity of each cell.
Statistics. Statistical analysis was performed using Prism 7.
One-way and two-way ANOVA were used to compare the
population mean of different treatment groups at 0.05
significant level. Tukey post-hoc test was further applied to
determine the statistical significance of mean difference among
the groups.
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